3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial - Concepedia

Concepedia

Publication | Closed Access

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

69

Citations

24

References

2024

Year

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego, Marco Colleoni, Agostina Stradella, Begoña Bermejo, Florence Dalenc, Santiago Escrivá-de-Romaní, Lourdes Calvo, Nuria Ribelles,

Breast OncologyMedicineChemotherapy De-escalationPathologyBreast CancerCancer TreatmentOncology

References

	Year	Citations

Page 1